Oragenics' Cash Surges on $15.2M Offering, But Losses Persist

TL;DR

**OGEN is burning cash and needs more capital to survive, despite a recent $15.2M lifeline; avoid until they show a clear path to profitability.**

AI Summary

Oragenics Inc. reported a net loss of $7.56 million for the nine months ended September 30, 2025, compared to a net loss of $7.22 million for the same period in 2024, representing a 4.7% increase in loss. The company's cash and cash equivalents significantly increased to $11.40 million as of September 30, 2025, from $864,840 at December 31, 2024, primarily due to financing activities. Research and development expenses decreased to $1.72 million for the nine months ended September 30, 2025, from $2.45 million in the prior year, a 29.7% reduction. General and administrative expenses, however, rose to $5.14 million from $4.75 million, an 8.2% increase. The company raised approximately $15.2 million in net proceeds from a public offering of Series H Preferred Stock and warrants in July 2025, which was crucial for funding operations. Despite this, an accumulated deficit of $224.34 million as of September 30, 2025, and recurring losses continue to raise substantial doubt about its ability to continue as a going concern, necessitating further capital raises beyond the current planning horizon.

Why It Matters

Oragenics' significant capital raise of $15.2 million from Series H Preferred Stock and warrants in July 2025 provides a critical, albeit temporary, lifeline for its ONP-002 development program targeting mild traumatic brain injury. For investors, this financing mitigates immediate liquidity concerns, extending the company's operational runway for at least 12 months, but the persistent net losses and accumulated deficit of $224.34 million signal continued high risk. Employees and customers of Oragenics will see continued progress on ONP-002, a potential first-in-class therapeutic, which could offer a competitive edge in the neurological conditions market if successful. However, the ongoing 'going concern' doubt underscores the precarious nature of its long-term viability without further substantial funding, impacting market confidence and competitive positioning.

Risk Assessment

Risk Level: high — Oragenics has an accumulated deficit of $224.34 million as of September 30, 2025, and incurred a net loss of $7.56 million for the nine months ended September 30, 2025. The company explicitly states that 'substantial doubt about our ability to continue as a going concern continues to exist unless and until we obtain additional capital to fund operations beyond the current planning horizon,' despite a recent $15.2 million financing.

Analyst Insight

Investors should exercise extreme caution and consider avoiding OGEN stock due to the significant 'going concern' risk and consistent net losses. Monitor future financing activities and clinical trial progress for ONP-002, but do not invest until the company demonstrates a clear, sustainable path to profitability and resolves its long-term funding challenges.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$12.71M

total Debt

$0.39M

net Income

$ -7.56M

eps

$ -5.16

gross Margin

N/A

cash Position

$11.40M

revenue Growth

N/A

Key Numbers

• $11.40M — Cash and cash equivalents (Increased from $864,840 at December 31, 2024, due to financing activities.)
• $7.56M — Net loss for nine months ended Sep 30, 2025 (Increased from $7.22 million in the prior year, indicating continued unprofitability.)
• $224.34M — Accumulated deficit (As of September 30, 2025, highlighting significant historical losses.)
• $15.2M — Net proceeds from Series H Preferred Stock and warrants (Raised in July 2025, providing critical liquidity.)
• $1.72M — Research and development expenses (Decreased by 29.7% for the nine months ended September 30, 2025, compared to $2.45 million in 2024.)
• $5.14M — General and administrative expenses (Increased by 8.2% for the nine months ended September 30, 2025, compared to $4.75 million in 2024.)
• 4,168,223 — Common stock shares outstanding (As of November 6, 2025, reflecting recent equity activity.)
• 1-for-30 — Reverse stock split ratio (Effected on June 3, 2025, to increase per-share price.)

Key Players & Entities

• ORAGENICS INC. (company) — Registrant
• Noachis Terra Inc. (company) — Wholly-owned subsidiary of Oragenics, Inc.
• Oragenics Australia Pty Ltd (company) — Wholly-owned subsidiary of Oragenics, Inc.
• ONP-002 (product) — Lead product candidate for mild traumatic brain injury
• Dawson James Securities Inc. (company) — At-the-Market Sales Agreement partner
• Ladenburg Thalmann (company) — Party in a legal settlement
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $224.34 million as of September 30, 2025, and has incurred recurring net losses, including $7.56 million for the nine months ended September 30, 2025. This raises substantial doubt about its ability to continue as a going concern, necessitating future capital raises.
• Dependence on Financing Activities [high — financial]: The significant increase in cash to $11.40 million from $864,840 was primarily due to financing activities, including a $15.2 million net proceeds from a Series H Preferred Stock and warrants offering in July 2025. This highlights a reliance on external funding to sustain operations.
• Increasing General and Administrative Expenses [medium — operational]: General and administrative expenses increased by 8.2% to $5.14 million for the nine months ended September 30, 2025, from $4.75 million in the prior year. This rise in overhead costs, despite a reduction in R&D, could impact profitability.
• Dilution from Equity Offerings [medium — financial]: The company has engaged in equity financing, such as the Series H Preferred Stock and warrants offering, which can lead to significant dilution for existing common stockholders. The number of common shares outstanding has fluctuated, and past reverse stock splits indicate efforts to manage share price.
• Reduced Research and Development Investment [medium — operational]: Research and development expenses decreased by 29.7% to $1.72 million for the nine months ended September 30, 2025, from $2.45 million in the prior year. A sustained reduction in R&D could impact future product development and competitiveness.

Industry Context

Oragenics operates in the biotechnology and pharmaceutical sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on external financing to fund their operations and clinical trials, facing intense competition and the risk of pipeline failures.

Regulatory Implications

As a biotechnology company, Oragenics is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in healthcare policy can significantly impact its operations and financial performance.

What Investors Should Do

1. Monitor future financing activities and their impact on share dilution.
2. Closely track R&D progress and spending to assess pipeline development and future growth potential.
3. Evaluate the company's ability to manage increasing G&A expenses.
4. Assess the long-term viability given the ongoing net losses and substantial accumulated deficit.
5. Review any updates on the company's strategy to address going concern uncertainties.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported net loss of $7.56 million and accumulated deficit of $224.34 million, highlighting ongoing financial challenges.
• 2025-07-01: Public offering of Series H Preferred Stock and warrants — Raised approximately $15.2 million in net proceeds, providing critical liquidity and funding for operations.
• 2025-06-03: 1-for-30 Reverse Stock Split — Effected to increase the per-share price of common stock, potentially improving market perception and compliance with exchange listing requirements.
• 2024-12-31: Year-end 2024 — Company had $864,840 in cash and cash equivalents, indicating a lower liquidity position prior to recent financing.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical unprofitability and significant losses over time, contributing to going concern doubts.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, requiring disclosure and potential mitigation strategies.)

Series H Preferred Stock

A class of preferred stock issued by the company, likely with specific rights and preferences over common stock. (The issuance of this stock in July 2025 was a key financing event that significantly boosted the company's cash position.)

Reverse stock split

A corporate action to reduce the number of outstanding shares of stock, thereby increasing the per-share price. (The 1-for-30 reverse split in June 2025 was an attempt to increase the stock price, often done to meet exchange listing requirements or improve investor perception.)

Net proceeds

The amount of money raised from issuing securities after deducting underwriting discounts and commissions, and other issuance expenses. (The $15.2 million in net proceeds from the Series H offering was crucial for the company's liquidity.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Oragenics Inc. reported a slightly increased net loss ($7.56 million vs. $7.22 million), despite a significant reduction in R&D expenses (down 29.7%). General and administrative expenses, however, rose by 8.2%. The most dramatic change is the substantial increase in cash reserves, from $864,840 to $11.40 million, driven entirely by recent financing activities, which also underscore the company's ongoing need for capital.

Key Financial Figures

• $0.001 — 8,223 shares of common stock, par value $0.001 per share, outstanding. Note Regardin

Filing Documents

• form10-q.htm (10-Q) — 638KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-25-021257.txt ( ) — 3172KB
• ogen-20250930.xsd (EX-101.SCH) — 27KB
• ogen-20250930_cal.xml (EX-101.CAL) — 30KB
• ogen-20250930_def.xml (EX-101.DEF) — 95KB
• ogen-20250930_lab.xml (EX-101.LAB) — 260KB
• ogen-20250930_pre.xml (EX-101.PRE) — 204KB
• form10-q_htm.xml (XML) — 294KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

OTHER INFORMATION

PART II. OTHER INFORMATION 20 Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 5. Other Information 22 Item 6. Exhibits 22

Signatures

Signatures 23 2 PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS Oragenics, Inc. Condensed Consolidated Balance Sheets (Unaudited) September 30, 2025 December 31, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 11,403,766 $ 864,840 Prepaid expenses and other current assets 1,301,778 607,670 Total current assets 12,705,544 1,472,510 Total assets $ 12,705,544 $ 1,472,510 Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable and accrued expenses $ 2,479,272 $ 1,355,867 Short-term notes payable, net of debt issuance costs 394,836 328,528 Total liabilities 2,874,108 1,684,395 Stockholders' equity (deficit): Preferred stock, no par value; 50,000,000 shares authorized; 432,122 Series H and 7,488,692 Series F outstanding at September 30, 2025, and 0 Series H and 7,488,692 Series F outstanding at December 31, 2024. - - Common stock, $ 0.001 par value; 350,000,000 shares authorized; 4,127,173 and 419,003 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively 4,127 419 Additional paid-in capital 234,169,098 216,573,868 Accumulated deficit ( 224,341,789 ) ( 216,786,172 ) Total stockholders' equity (deficit) 9,831,436 ( 211,885 ) Total liabilities and stockholders' equity (deficit) $ 12,705,544 $ 1,472,510 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3 Oragenics, Inc. Condensed Consolidated Statements of Operations (Unaudited) 2025 2024 2025 2024 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 930,894 $ 879,041 $ 1,722,115 $ 2,449,234 General and administrative 2,192,879 1,558,239 5,142,087 4,754,149 Total operating expenses 3,123,773 2,437,280 6,864,202 7,203,383 Loss from operations ( 3,123,773 ) ( 2,437,280 ) ( 6,864,202 ) ( 7,203,383 ) Other income (expense)

View Full Filing

View this 10-Q filing on SEC EDGAR